Assessing the utility of cabazitaxel in mCRPC.
作者信息
North Scott A
机构信息
Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
出版信息
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):111-2. doi: 10.5489/cuaj.3721.
Abstract
摘要
相似文献
1
Assessing the utility of cabazitaxel in mCRPC.评估卡巴他赛在转移性去势抵抗性前列腺癌（mCRPC）中的效用。
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):111-2. doi: 10.5489/cuaj.3721.
2
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.卡巴他赛与他喹莫德用于多线治疗后的转移性去势抵抗性前列腺癌（mCRPC）男性患者的Ib期试验：CATCH试验
Prostate. 2017 Mar;77(4):385-395. doi: 10.1002/pros.23277. Epub 2016 Nov 16.
3
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.接受卡巴他赛治疗的转移性去势抵抗性前列腺癌患者循环肿瘤细胞的计数与特征分析
Cancers (Basel). 2019 Aug 20;11(8):1212. doi: 10.3390/cancers11081212.
4
Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel.接受卡巴他赛治疗的去势抵抗性前列腺癌患者的风险分层
Mol Clin Oncol. 2018 Dec;9(6):683-688. doi: 10.3892/mco.2018.1724. Epub 2018 Sep 19.
5
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry.基线特征对转移性去势抵抗性前列腺癌患者卡巴他赛治疗持续时间的影响：同情用药/扩大使用计划和CAPRISTANA注册研究的事后分析
Cancers (Basel). 2020 Apr 17;12(4):995. doi: 10.3390/cancers12040995.
6
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.研究者回顾性分析了多西他赛治疗失败的转移性去势抵抗性前列腺癌患者序贯应用卡巴他赛和醋酸阿比特龙的疗效。
Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.
7
Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.在接受卡巴他赛治疗的日本转移性去势抵抗性前列腺癌患者中，德瑞蒂斯比值（天冬氨酸转氨酶/丙氨酸转氨酶）作为一种重要的预后生物标志物而非预测性生物标志物的意义。
Anticancer Res. 2018 Jul;38(7):4179-4185. doi: 10.21873/anticanres.12711.
8
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.卡巴他赛方案可抑制前列腺癌细胞的生长，并增强色素上皮衍生因子（PEDF）的抗肿瘤特性，且具有不同的疗效和毒性。
Prostate. 2018 Sep;78(12):905-914. doi: 10.1002/pros.23647. Epub 2018 May 10.
9
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.多西他赛和阿比特龙治疗后进展的转移性去势抵抗性前列腺癌（mCRPC）患者中卡巴他赛联合阿比特龙的I/II期试验
Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441.
10
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.卡巴他赛联合 188Re-羟乙基二膦酸盐治疗多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者的 1 期临床试验：ReCab 试验。
Clin Nucl Med. 2017 Jun;42(6):415-420. doi: 10.1097/RLU.0000000000001604.
本文引用的文献
1
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.卡巴他赛在加拿大接受或未接受过阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的疗效、生活质量及安全性
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):102-9. doi: 10.5489/cuaj.3470.
2
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
3
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
4
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
5
Abiraterone in metastatic prostate cancer without previous chemotherapy.阿比特龙治疗既往未接受化疗的转移性前列腺癌。
N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10.
6
Increased survival with enzalutamide in prostate cancer after chemotherapy.恩杂鲁胺可提高化疗后前列腺癌患者的生存率。
N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
7
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?多西他赛治疗后 CYP17A1 抑制剂阿比特龙的抗肿瘤活性：交叉耐药的临床证据？
Ann Oncol. 2012 Nov;23(11):2943-2947. doi: 10.1093/annonc/mds119. Epub 2012 Jul 5.
8
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
9
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
10
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
Zotero 插件